监管与产业动态· FierceBiotech·· 20 hours agoPickScore71
Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer win - Fierce Biotech
In brief
Merck KGaA has acquired Silence for approximately $1.3 billion. The deal was formally launched after Silence's siRNA drug delivered positive topline results in a phase 2 trial in blood cancer.
Why it matters
The roughly $1.3 billion acquisition price is tied directly to the siRNA drug's positive phase 2 readout in blood cancer, offering a valuation benchmark for comparable siRNA assets.
Source: 监管与产业动态